NEOD001
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Systemic (AL) Amyloidosis
Conditions
Primary Systemic (AL) Amyloidosis
Trial Timeline
Feb 1, 2015 → May 1, 2018
NCT ID
NCT02312206About NEOD001
NEOD001 is a phase 3 stage product being developed by Prothena for Primary Systemic (AL) Amyloidosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02312206. Target conditions include Primary Systemic (AL) Amyloidosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03154047 | Phase 2 | Terminated |
| NCT02613182 | Phase 2 | Terminated |
| NCT02312206 | Phase 3 | Terminated |
| NCT01707264 | Phase 1/2 | Completed |
Competing Products
20 competing products in Primary Systemic (AL) Amyloidosis